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Abstract 19	
Background: We investigated the pharmacokinetics (PK) of atazanavir/cobicistat and 20	
darunavir/cobicistat once-daily over 72h following drug intake cessation in plasma, saliva 21	
and urine.  22	
Materials and methods: Healthy volunteers received a fixed-dose-combination of 23	
atazanavir/cobicistat 300/150mg once-daily for 10 days, followed by a 10-day washout 24	
period and then a fixed-dose-combination of darunavir/cobicistat 800/150mg once-daily for 25	
10 days. Full PK profiles were assessed for each phase for 72h following day 10 and 26	
parameters determined to the last measurable concentration in plasma, saliva and urine by 27	
non-compartmental methods.  28	
Results: Sixteen subjects completed the study. Geometric mean (GM) terminal elimination 29	
half-life to 72h of atazanavir and darunavir were 6.77h and 6.35h. 30	
All subjects had atazanavir concentrations above the suggested minimum effective 31	
concentration of 150ng/mL 24h post-dose and 14/16 subjects had concentrations higher 32	
than this target at 30h post-dose (GM of 759 and 407ng/mL). Thirteen/16 subjects had 33	
darunavir concentrations higher than the target of 550ng/mL at 24h post-dose, and 5/16 34	
subjects had concentrations higher than the target at 30h post-dose (GM of 1033 and 35	
382ng/mL). Cobicistat half-life to 72h was 4.21h with atazanavir and 3.62h with darunavir. 36	
GM saliva and urine atazanavir and darunavir C24h were 141ng/mL and 43ng/mL, and 37	
24857ng/mL and 11878ng/mL. Concentrations decay in saliva/urine mirrored plasma 38	
concentrations for both drugs. 39	
Conclusions: Different concentration decay patterns were seen for atazanavir and 40	
darunavir, which may be partially explained by cobicistat half-life (longer with atazanavir than 41	
darunavir). For the first time, we also measured drug PK forgiveness in saliva and urine, 42	
which represent easier markers of adherence.  43	
44	
Introduction 45	
Ritonavir-boosted protease inhibitors such as atazanavir and darunavir have been used for 46	
many years and are an instrumental option as third agents in the management of HIV.1 47	
Advantages of pharmacological boosting include increased drug exposure and a prolonged 48	
half-life thereby reducing pill burden, allowing once daily dosing, and in the case of PIs, 49	
achieving a high genetic barrier to resistance.2 50	
The use of ritonavir as a boosting agent, however, presents a number of disadvantages. 51	
Consequently, cobicistat, a structural analogue without antiviral activity, is now available as 52	
an alternative pharmacokinetic enhancer. Unlike ritonavir, good solubility lends cobicistat to 53	
co-formulation and a lack of enzyme-inducing activity, potentially offers a better drug 54	
interaction profile.3 It inhibits cytochrome P450 3A4 (CYP3A4) with a potency similar to that 55	
of ritonavir and at a dosage of 150 mg once daily, provides bioequivalent exposures of 56	
atazanavir (300 mg once daily) and darunavir (800 mg once daily)4 compared with those 57	
observed with 100 mg of ritonavir once daily.3 58	
We previously presented data on the pharmacokinetic forgiveness of once-daily ritonavir-59	
boosted darunavir and atazanavir, showing, a favorable atazanavir pharmacokinetic tail (PK) 60	
tail and a slight increase in decline rate for both protease inhibitors as ritonavir 61	
concentrations decrease.5 62	
In vivo data for atazanavir/cobicistat and darunavir/cobicistat (both available in fixed dose 63	
combination) concentration decay after intake cessation have not, however, been previously 64	
described. 65	
PK forgiveness is important in clinical practice in order to understand the management of 66	
late and missed doses, particularly with protease inhibitors as their use is increasingly 67	
targeted to complex cases of viral resistance, poor adherence and extensive antiretroviral 68	
treatment experience.1 Drug persistence in plasma is dependent on its half-life (which itself 69	
depends on clearance and volume of distribution).6 As such, antiretroviral agents with longer 70	
half-lives may be more forgiving and allow for forgotten doses, especially if drug 71	
concentrations remain therapeutic until the patient reinitiates drug intake.  72	
In addition to the above, there is a paucity of data in the literature on protease inhibitor 73	
exposure in other matrices such as saliva and urine, with one report available7 and no study 74	
on drug levels in saliva or urine post cessation of drug intake. Sampling of saliva and urine is 75	
significantly less invasive than venipuncture and therefore may be a valuable measure of 76	
adherence in clinical practice in future. This has been shown to be useful in other infectious 77	
diseases where long-term treatment, optimal drug absorption and adherence are 78	
fundamental, like tuberculosis (TB), where urine colorimetry can detect low rifampicin 79	
plasma concentrations in HIV/TB co-infected individuals.8 80	
 81	
The object of this study was therefore to investigate the steady-state PK of 82	
atazanavir/cobicistat and darunavir/cobicistat once daily dosing over 72 hours following drug 83	




Eligible participants were male and non-pregnant and non-lactating female healthy 88	
volunteers aged between 18 and 65 years with a BMI between 18 and 35 kg/m2. Participants 89	
were excluded if they had any significant acute or chronic medical illness; abnormal physical 90	
examination, ECG or clinical laboratory determinations; positive screens for HIV, hepatitis B 91	
or C; current or recent (within three months) gastrointestinal disease; clinically relevant 92	
alcohol or drug use that the investigator felt would adversely affect compliance with trial 93	
procedures; exposure to any investigational drug or placebo within three months of the first 94	
dose of the study drug; use of any other drugs, including over the counter medications and 95	
herbal preparations, within two weeks of the first dose of the study drug; and previous allergy 96	
to any of the constituents of the pharmaceuticals administered during the trial. 97	
Study design 98	
This was an open-label, two-phase, 33-day PK trial carried out at the Clinical Trial Unit of the 99	
St. Stephen’s Centre, Chelsea, and Westminster Hospital, London, United Kingdom.  100	
At screening, participants had a clinical assessment and routine laboratory investigations 101	
performed. The safety and tolerability of study medications were evaluated throughout the 102	
trial (on days 1, 5, 10, 21, and 30, and at follow-up) using the NIAID Division of AIDS table 103	
for grading the severity of adult and pediatric adverse events to characterize abnormal 104	
findings (published 2004), vital signs, physical examinations and clinical laboratory 105	
investigation. After successful screening, during the first study phase, volunteers were 106	
administered fixed-dose combination atazanavir/cobicistat at 300/150 mg once daily 107	
(Evotaz®) in the morning for 10 days. On study days 10 to 13, atazanavir and cobicistat 108	
plasma concentrations were assessed pre-dose and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 30, 109	
36, 48, 60, and 72 hours post dose. After a washout period of seven days, all subjects were 110	
administered fixed-dose combination darunavir/cobicistat at 800/150 mg once daily 111	
(Rezolsta®) for 10 days. On study days 30 to 33, darunavir and cobicistat plasma 112	
concentrations were assessed pre-dose and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48, 113	
60, and 72 hours post dose. On the PK days, study medication intake with a standardized 114	
breakfast (626 kcal) and 240 mL of water was witnessed. 115	
Analytical and PK methods 116	
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at each 117	
time-point, immediately inverted several times and then kept on ice or refrigerated until 118	
centrifugation. Within 30 min of blood collection, each blood sample was centrifuged for 10 119	
min at 2000 g at 4C. Plasma was then aliquoted equally into three 2.0 mL tubes (Sarstedt, 120	
Germany) and stored at -20C. 121	
On the PK days, saliva (study subjects were asked to spit) and a minimum of 5 mL of urine 122	
were collected into universal containers at each scheduled sampling time (24, 30, 36, 48, 60, 123	
and 72 hours post-dose). 124	
Samples were shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The 125	
laboratory participates in an external quality assurance scheme (KKGT, the Netherlands). 126	
Quantification of atazanavir, darunavir, and cobicistat 127	
Concentrations of atazanavir, darunavir and cobicistat in plasma, saliva and urine were 128	
measured using validated high-pressure liquid chromatography–tandem mass spectrometry 129	
methods.9 The lower limits of quantification (LLQ) for the plasma analyses was 10 ng/mL for 130	
atazanavir, cobicistat and 15 ng/mL for darunavir. For concentrations below the assay limit 131	
of quantification, a value of one-half of the quantification limit was used.  132	
The saliva assay was validated over a calibration range of 3.7-500 ng/mL for all three 133	
analytes. Accuracy (percentage bias) was between 99.5% and 108.2% (atazanavir), 94.2% 134	
and 101.2% (darunavir) and 92.3% and 104.0% (cobicistat), and precision was between 135	
2.8% and 5.4% (atazanavir), 4.4% and 6.0% (darunavir) and 3.1% and 6.5% (cobicistat). 136	
Data analysis 137	
The calculated PK parameters for plasma atazanavir, darunavir and cobicistat were the 138	
plasma concentration measured 24 hours after the observed dose (C24h), the maximum 139	
observed plasma concentration (Cmax) and the area under the plasma concentration curve 140	
from 0 to 24 hours (AUC0–24). The half-life was determined from the elimination phase within 141	
the normal dosing interval of 0–24 hours and as a terminal elimination half-life to the last 142	
measurable concentration within 72 hours. All PK parameters were calculated using actual 143	
blood sampling time and non-compartmental modeling techniques (WinNonlin Phoenix, 144	
version 6.1; Pharsight, Mountain View, CA). Descriptive statistics, including geometric mean 145	
(GM) and 95% confidence intervals (95% CI) were calculated for atazanavir, darunavir and 146	
cobicistat plasma PK parameters. GMs were compared with the suggested therapeutic 147	
targets that were established in vivo (atazanavir) and in vitro (darunavir) and are available in 148	
the current literature for each drug.10,11 These targets estimate the minimum effective 149	
concentration to be equivalent to 10 times the protein binding corrected inhibitory 150	
concentration at 50% [IC50] for wild -type virus for atazanavir and for darunavir at150 ng/mL 151	
and 550 ng/mL, respectively.  152	
Inter individual variability in drug PK parameters was expressed as a percentage coefficient 153	
of variation [CV, (standard deviation/mean)×100]. 154	
Urine and saliva concentrations were described as GM and 95% CI at each sampling time-155	
point over the concentration decay curves. Plasma drug concentrations were correlated to 156	
saliva and urine concentrations by linear regression analysis. 157	
Ethics 158	
The study protocol was approved by the Bloomsbury Research Ethics Committee, London, 159	
United Kingdom (REC reference: 15/LO/1596, IRAS project ID: 184771) as well as by the 160	
Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom and 161	
was conducted according to Good Clinical Practice and the Declaration of Helsinki (EudraCT 162	
Number: 2015-002956-28). Written informed consent was obtained from eligible participants 163	
after screening and counseling, on the same day.  164	
Results 165	
Study population 166	
Sixteen volunteers completed all phases of the study. Median (range) age and median body 167	
mass index (BMI) were 38 (24 to 54) years, and 25 (22 to 31) kg/m2, respectively. Nine were 168	
female, nine described themselves as Caucasians, six as black, and two as Asian.169	
Atazanavir plasma pharmacokinetics 170	
Atazanavir GM plasma concentration versus time curves when combined with cobicistat are shown in 171	
Figure 1 and PK parameters are summarized in Table 1.  172	
The GM terminal elimination half-life to 72 hours of atazanavir was 6.77 hours (95% CI 6.2-7.5). This 173	
value was lower than the half-life measured over the dosing interval of 24 hours (GM 9.69 hours; 95% 174	
CI 9.2-12.8).  175	
All subjects had atazanavir concentrations above the suggested target 24 hours post-dose (GM 759.2 176	
ng/mL). Two/16 and 13/16 subjects had concentrations below the target at 30 and 48 hours post-177	
dose, respectively (GM 407.0 and 65.9 ng/mL, Table 2). 178	
The inter-individual variability in atazanavir C24h was 73%. 179	
Darunavir plasma pharmacokinetics 180	
Darunavir GM plasma concentration versus time curves when combined with cobicistat are shown in 181	
Figure 1 and PK parameters are summarized in Table 1.  182	
Darunavir GM terminal elimination half-life was 6.4 hours (95% CI 5.9-7.0). This value was lower than 183	
the half-life measured over the dosing interval of 24 hours (GM 10.4h; 95% CI 9.2-12.9). 184	
Three/16 subjects had darunavir concentrations below the suggested target 24 hours post-dose and 185	
11/16 had concentrations lower than the target at 30 hours (GM 1032.6 and 381.7 ng/mL, Table 2). 186	
The inter-individual variability in darunavir C24h values was 65%. 187	
Cobicistat plasma pharmacokinetics 188	
Steady-state cobicistat PK parameters when combined with atazanavir and darunavir are reported in 189	
Table 3. 190	
When combined with atazanavir, the GM terminal elimination half-life to the last measurable 191	
concentration for cobicistat was 4.2 hours (95% CI 3.9-4.7) and over the dosing interval of 24 hours 192	
was 4.4 hours, 95% CI 4.0–5.2). 193	
These were higher than when cobicistat was combined with darunavir, where the GM terminal 194	
elimination half-life to the last measurable concentration was 3.6 hours (95% CI 3.3-4.0) and over the 195	
dosing interval of 24 hours was 3.8 (95% CI 3.5-4.3). 196	
Saliva and urine concentrations 197	
GM saliva and urine concentrations measured between 24 and 72 hours post-dose are illustrated in 198	
Figure 2. 199	
Although saliva concentrations of atazanavir and darunavir are lower than those measured in plasma 200	
(GM C24h saliva:plasma ratios were 0.19 and 0.04, respectively, saliva PK profiles showed the same 201	
concentration decay trends of plasma. 202	
On the other hand, urine concentrations were higher than in plasma with urine:plasma ratios of 32.7 203	
for atazanavir and 11.5 for darunavir. 204	
Plasma-saliva correlation coefficients were R2=0.533 for atazanavir and R2=0.64 for darunavir. 205	
Plasma atazanavir concentrations correlated significantly with urine atazanavir concentrations 206	
(R2=0.78). Plasma darunavir concentrations also correlated with urine darunavir (R2=0.65) even 207	
though the relationship did not appear as strong as for atazanavir.  208	
Safety and tolerability 209	
Treatment was generally well tolerated, and no serious adverse events occurred during the study. As 210	
expected because extensively described in the literature,12 the most common adverse events 211	
observed throughout the study were scleral icterus and hyperbilibirubinaemia (during the 212	




We report for the first time the steady state PK of atazanavir and darunavir in plasma, saliva and 217	
urine over 72 hours following drug intake cessation in HIV negative healthy volunteers to describe the 218	
PK forgiveness of these two commonly used PIs when boosted by cobicistat. 219	
Concentrations of atazanavir were measurable in all subjects 48 hours post dose and in 11 and 2 220	
subjects 60 and 72 hours post dose. Importantly 14/16 subjects had concentrations above the 221	
suggested MEC of 150 ng/mL and the remaining two had concentrations equal to 148 ng/mL 30 222	
hours post dose, suggesting that a six hour drug intake delay would not compromise optimal drug 223	
exposure and efficacy. Similarly, darunavir concentrations were measurable in 13/16, 6/16, and 2/16 224	
subjects 48, 60, and 72 hours post dose, respectively. However, 3/16 study individuals had 225	
concentrations below the suggested 550 ng/mL cut-off 24 hours post dose, and only five had 226	
concentrations above 550 ng/mL 30 hours post dose. Whether this is clinically significant is unclear 227	
and more data in patients who are poorly adherent to darunavir/cobicistat will hopefully emerge in the 228	
near future to help clinicians prescribing the optimal booster in certain complex clinical situations (e.g. 229	
suboptimal viral replication suppression). 230	
Notably, measurements of atazanavir PK forgiveness in the presence of cobicistat are similar to those 231	
in the presence of ritonavir [6], where atazanavir terminal elimination half-life was 6.77 hours with 232	
cobicistat versus 6.74 hours with ritonavir. Darunavir terminal elimination half-life was measured to be 233	
6.35 hours with cobicistat versus 6.48 hours with ritonavir. 234	
While there is no doubt of protease inhibitor robustness in antiretroviral naïve people living with HIV 235	
(PLWH), in patients who are inclined to poor compliance or harbor viral resistance, PK forgiveness 236	
knowledge may be particularly important. 237	
However, the clinical significance of our findings is unclear as pharmacodynamics (PD) data on what 238	
concentrations are needed to ensure long-term viral suppression maintenance in PLWH are 239	
unavailable and it is often unclear how delayed a dose is or how many doses can be omitted before 240	
efficacy is lost.  241	
A further study limitation is that it was conducted in HIV negative healthy volunteers not to impose 242	
antiretroviral dose delays in PLWH. Data on drug exposure potential differences between PLWH and 243	
HIV negative volunteers are controversial but must be taken into consideration.13 244	
Cobicistat terminal half-life was 4.21 hours with atazanavir and 3.62 hours with darunavir, therefore 245	
shorter than ritonavir terminal half-life with atazanavir (5.03 hours) and darunavir (6.30 hours), 246	
respectively. 247	
Both cobicistat and ritonavir inhibit the cytochrome P450 3A4 (CYP3A4), thereby reduce the 248	
metabolism of concomitantly administered protease inhibitors and lead to enhanced drug exposure.3 249	
Although very similar, the two drugs are not identical and their relationship with the therapeutic agent 250	
they enhance may explain concentration decay patterns. Importantly, the rates of decline of both 251	
atazanavir and darunavir slightly increased as cobicistat concentrations declined. Cobicistat itself is 252	
metabolized by CYP3A4 and when given with atazanavir, a moderate CYP 3A4 inhibitor,14 it achieves 253	
slightly higher concentrations than when co-administered with darunavir, which on the other hand is 254	
an inducer of CYP3A4.14 255	
The inter individual variability (CV) in atazanavir and darunavir C24h was 73% and 65% with cobicistat, 256	
therefore similar to those previously measured with ritonavir (81% and 62%, respectively).5 257	
Drug saliva and urine pharmacokinetic elimination profiles mirrored that of plasma, suggesting 258	
potential use of these matrices’ as a marker of adherence/PK forgiveness. 259	
Atazanavir/cobicistat and darunavir/cobicistat were well tolerated, with adverse events limited to 260	
expected increases in indirect bilirubin levels during the atazanavir/cobicistat study phase. 261	
In conclusion, our data report the PK forgiveness of atazanavir/cobicistat and darunavir/cobicistat and 262	
contribute to the understanding of the extent of whether drug doses can be delayed or missed. This is 263	
important in the context of chronic diseases, where sub-optimal compliance to medications may be 264	
common15 and therefore within the HIV medicine field where repercussions of insufficient drug 265	
exposure can be serious since if drug concentrations drop to sub-therapeutic levels after missed 266	
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Legends to Tables and Figures 288	
Table 1: Plasma atazanavir (ATV) and darunavir (DRV) steady state pharmacokinetic (PK) 289	
parameters, expressed as geometric mean (GM) and 95% confidence intervals (CI), range (minimum, 290	
Min and maximum, Max) and coefficient of variation (CV), measured over 24 and 72 hours. 291	
Cmax = maximum concentration, AUC = area under the curve, C24 = 24 hour post-dose concentration, 292	
Clast = last measurable concentration, t1/2 = half-life. 293	
Table 2: Plasma concentrations of atazanavir and darunavir measured at 24, 30, 36, 48 hours post 294	
dose, expressed as geometric mean (GM) and range, and number (N) of subjects below target per 295	
time-point. 296	
Table 3: Cobicistat steady state plasma pharmacokinetic (PK) parameters, expressed as geometric 297	
mean (GM) and 95% confidence (CI), range (minimum, Min and maximum, Max) and coefficient of 298	
variation (CV), measured over 24 and 72 hours with atazanavir (ATV) and darunavir (DRV). 299	
Cmax = maximum concentration, AUC = area under the curve, C24 = 24 hour post-dose concentration, 300	
Clast = last measurable concentration, t1/2 = half-life. 301	
Figure 1: Geometric mean steady state plasma concentrations of atazanavir (ATV, black) and 302	
darunavir (DRV, grey) when boosted by 150 mg of cobicistat over 72 hours (black dashed with ATV 303	
and grey dashed with DRV). 304	
Figure 2: A. Saliva atazanavir (ATV) and cobicistat (COBI) B. Saliva darunavir (DRV) and cobicistat 305	
(COBI) C. Urine atazanavir (ATV) and cobicistat (COB) D. Urine darunavir (DRV) and cobicistat 306	
(COBI) concentration decay between 24 and 72 hours post-dose expressed as geometric mean (GM 307	
-  continuous lines) and  90% confidence interval (90%CI – dashed lines). 308	
  309	
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Table	1	347	
	348	
  PK parameters ATV 300mg OD     






n 9.69 6.77 3718.85 759.20 6.36 37713.15 46128.91 
low 95% 9.24 6.22 3308.00 612.57 1.29 32661.47 38592.12 
up 95% 12.83 7.54 4940.55 1290.07 19.00 51555.93 67844.20 
Min 6.32 5.42 844.97 256.10 5.00 11413.66 14057.77 
Max 19.26 9.96 7282.82 2666.54 77.28 83763.28 128322.91 
CV (%) 33 20 40 73 178 46 56 
  PK parameters  DRV 800mg OD 






n 10.41 6.35 5515.02 1032.56 8.80 58099.81 66710.08 
low 95% 9.18 5.88 4949.07 837.92 6.01 51464.12 58145.46 
up 95% 12.94 7.03 6566.03 1625.74 14.44 70391.27 83214.29 
Min 5.23 4.25 2855.55 372.96 7.50 26404.49 29317.22 
Max 19.15 8.48 8365.97 3359.34 41.13 111312.19 141982.09 





































Geomean 4.43 4.21 1408.02 49.59 5.00 10553.97 10923.56 
low 95% 3.95 3.87 1293.37 42.07 5.00 9589.47 9904.56 
up 95% 5.19 4.69 1577.76 79.63 5.00 12058.87 12535.27 
Median 4.32 4.17 1381.49 56.35 5.00 10569.53 10735.04 
Min 3.14 3.21 929.72 14.15 5.00 7825.70 8145.20 
Max 8.39 6.13 1986.37 156.24 5.00 14680.79 15068.30 
CV 28 19 20 63 0 23 24 





Geomean 3.81 3.62 1250.25 27.56 5.00 9532.06 9681.21 
low 95% 3.49 3.34 1149.77 22.29 5.00 8677.55 8790.87 
up 95% 4.29 3.98 1392.73 51.37 5.00 10857.17 11078.72 
Min 2.59 2.59 932.46 5.00 5.00 6167.33 6254.42 
Max 5.60 5.55 1867.32 120.90 5.00 14425.77 14933.25 
CV 21 18 20 81 0 23 23 
	356	
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